Goldman Sachs Upgrades BioMarin Pharmaceutical To Buy

By: via Benzinga
Goldman Sachs upgraded BioMarin Pharmaceutical (NASDAQ: BMRN) from Neutral to Buy. The price target for BioMarin Pharmaceutical has ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.